A patent from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. describes bicyclic heterocycle 5'-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Sanofi SA has synthesized pyridoimidazolone compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors potentially useful for the treatment of cancer.
The Wiskott-Aldrich syndrome protein (WASp) is expressed exclusively in hematopoietic cells and presents either an autoinhibited or activated conformation. EG-011 is a first-in-class activator of the autoinhibited form of WASp designed for the treatment of hematological cancers.
Work at Horizon Omics Biotech Ltd. has led to the identification of quinolone derivatives reported to be useful for the treatment of cancer, autoimmune diseases, viral, bacterial and fungal infections.
Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have patented C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
A team from Nanjing Leads Biolabs Co. Ltd. presented the discovery and preclinical characterization of LBL-042, a novel bispecific antibody designed to simultaneously target PD-1 and LILRB1/2, with the aim of improving immune evasion of tumor microenvironment and potentially overcoming resistance to immuno-oncology therapy.
Changchun Genescience Pharmaceuticals Co. Ltd. has reported GSC-000829, a novel and selective FGFR2/FGFR3 inhibitor being developed for the potential treatment of cancer.
DAN-222 is a polymeric nanoparticle covalently conjugated with the topoisomerase I inhibitor camptothecin, which has previously demonstrated promising clinical activity in heavily pretreated patients with breast cancer (NCT05261269).
Recurrence rates and acquired treatment resistance in colorectal cancer have been linked to colorectal cancer stem cells, which are a subpopulation of slowly dividing cells within the tumor environment.
RSS
